Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Partow Kebriaei

Showing results (91-100 of 346) with videos related to

Pageof 35
Sort By:
American Journal of Hematology|June 7, 2021
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantationKylee L Martens, Christopher I Amos, Cristhiam Rojas Hernandez, et al.
Cancer Research|May 12, 2011
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignanciesHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 2010
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 lociStefan O Ciurea, Rima M Saliba, Gabriela Rondon, et al.
British Journal of Haematology|February 3, 2023
Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapyXin Shelley Wang, Samer A Srour, Tito Mendoza, et al.
Cancer|April 9, 2026
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemiaHagop Kantarjian, Wei Qiao, Nitin Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2014
Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantationBetul Oran, Piyanuch Kongtim, Uday Popat, et al.
Haematologica|March 26, 2026
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemiaDaniel Nguyen, Elias Jabbour, Hagop M Kantarjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic SyndromesHans C Lee, Rima M Saliba, Gabriela Rondon, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Pageof 35

Showing results (91-100 of 346) with videos related to

Sort By:
Pageof 35
American Journal of Hematology|June 7, 2021
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantationKylee L Martens, Christopher I Amos, Cristhiam Rojas Hernandez, et al.
Cancer Research|May 12, 2011
Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignanciesHarjeet Singh, Matthew J Figliola, Margaret J Dawson, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 26, 2010
Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one human leukocyte antigen mismatched related donors using HLA typing at 10 lociStefan O Ciurea, Rima M Saliba, Gabriela Rondon, et al.
British Journal of Haematology|February 3, 2023
Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapyXin Shelley Wang, Samer A Srour, Tito Mendoza, et al.
Cancer|April 9, 2026
Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemiaHagop Kantarjian, Wei Qiao, Nitin Jain, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic LeukemiaDavid I Marks, Partow Kebriaei, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 24, 2014
Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantationBetul Oran, Piyanuch Kongtim, Uday Popat, et al.
Haematologica|March 26, 2026
Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemiaDaniel Nguyen, Elias Jabbour, Hagop M Kantarjian, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 18, 2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic SyndromesHans C Lee, Rima M Saliba, Gabriela Rondon, et al.
British Journal of Haematology|May 10, 2017
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term resultsSamer A Srour, Shaoying Li, Uday R Popat, et al.
Pageof 35